Skip to main content
. 2019 Apr 29;3(9):1356–1367. doi: 10.1182/bloodadvances.2018029140

Table 1.

Patient and disease characteristics

Characteristic All patients (N = 71) RT only (n = 36) Combined therapy (n = 29) RT-only vs combined therapy, P Systemic therapy only (n = 6)
Age
 Median (range), y 39 (18-73) 38 (18-69) 40 (22-73) 49 (31-68)
 ≥45 y 30 (42) 15 (42) 11 (38) .803 4 (67)
Male 53 (75) 26 (72) 23 (79) .573 4 (67)
Disease stage
 I 28 (39) 22 (61) 6 (21) .001 0
 II 43 (61) 14 (39) 23 (79) 6 (100)
Disease location
 Above diaphragm 56 (79) 32 (89) 21 (72) .114 3 (50)
 Below diaphragm 15 (21) 4 (11) 8 (28) 3 (50)
 Mediastinal involvement 3 (4) 2 (6) 1 (3) 1.00 0
ECOG PS
 0 64 (90) 33 (92) 27 (93) 1.00 4 (67)
 1 7 (10) 3 (8) 2 (7) 2 (33)
B symptoms 5 (7) 0 4 (14) .035 1 (17)
Extranodal disease 4 (7) 1 (3) 3 (10) .316 0
Histologic pattern
 Typical 48 (68) 28 (78) 17 (59) .113 3 (50)
 Variant 23 (32) 8 (22) 12 (41) 3 (50)
PET-CT imaging 60 (85) 29 (81) 25 (86) .742 6 (100)
Tumor size*
 Median (range), cm 3.0 (1.2-8.5) 3.0 (1.4-6.9) 3.3 (1.2-8.5) 2.8 (1.2-3.0)
 ≥5 cm 8 (11) 3 (8) 5 (18) .282 0

Unless otherwise noted, all data are n (%).

ECOG PS, Eastern Cooperative Oncology Group Performance Status score.

*

Tumor size was unavailable for 1 patient.